Softwr

Research · head to head

Genedata vs Terra

Genedata logo

Genedata

Research

Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher

From
On request
Rated
-
Full reviewWebsite
Terra logo

Terra

Research

Open biomedical research platform for genomic analysis, priced only by the cloud you consume

From
Free
Rated
-
Full reviewWebsite

The short version

  • Only Terra has a free tier, so it costs nothing to try first.
  • Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; Terra the absence of a licence fee hides the real cost driver: an idle notebook virtual machine left running overnight, or a workspace bucket full of intermediate workflow outputs, quietly consumes grant money with no vendor invoice to prompt a review.
  • They diverge on capability: Genedata covers Screener, Terra covers No platform licence fee.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Genedata and Terra actually diverge.

Attributes where Genedata and Terra differ
AttributeGenedataTerra
Starting priceOn requestFree
Pricing modelquoteOpen source, no licence fee
Free tierNoYes
PlatformsWeb, On-premise, Private cloudWeb, Google Cloud, Microsoft Azure

Identical on both: user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Genedata

  • Screener
  • Biologics
  • Bioprocess
  • Expressionist
  • Selector
  • Profiler
  • Instrument integration
  • GxP-capable deployments

Only in Terra

  • No platform licence fee
  • Cloud pass-through billing
  • WDL workflow execution
  • Notebook environments
  • Controlled-access data
  • Workspace sharing
  • Compliance posture
  • Multi-cloud

What people use each for

The jobs each tool is most often brought in to do.

Genedata

  • A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Terra
  • A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Terra
  • A process development group standardising bioprocess run data across sites for modelling and scale-upnot Terra
  • A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Terra

Terra

  • A genomics lab running whole-genome alignment and variant calling pipelines without provisioning or maintaining a local clusternot Genedata
  • A consortium sharing controlled-access human data across institutions where the data cannot be copied to each sitenot Genedata
  • A health system analysing patient genomic data under a HIPAA business associate agreementnot Genedata
  • A federal or federally funded project needing FedRAMP Moderate authorisation for its analysis environmentnot Genedata

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Genedata

  • There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
  • Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
  • Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
  • Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
  • Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.

Terra

  • The absence of a licence fee hides the real cost driver: an idle notebook virtual machine left running overnight, or a workspace bucket full of intermediate workflow outputs, quietly consumes grant money with no vendor invoice to prompt a review.
  • Cost governance is entirely the customer responsibility, and grant-funded groups without a cloud engineer routinely overspend before anyone reads the Google or Azure bill in enough detail to find the cause.
  • It assumes genuine bioinformatics competence: writing or adapting WDL workflows, managing data tables and debugging failed tasks are all on you, so a wet lab without computational staff cannot use it productively.
  • Feature parity between the Google Cloud and Azure deployments is not identical, so a decision on cloud provider constrains which capabilities and datasets you can reach and is expensive to reverse later.
  • It is a research platform rather than a regulated clinical system: it is not a validated GxP environment and does not carry the qualification package a diagnostic or submission workflow would require, so clinical use needs additional infrastructure and validation you provide yourself.

Pricing, plan by plan

Genedata

On request
  • Genedata platform licence$undefined/year
    • Each platform, such as Screener or Biologics, licensed separately
    • Annual enterprise subscription scoped on users, sites and data volume
    • Implementation and scientific configuration services quoted as a separate programme

Terra

Free
  • Terra platformFree
    • No charge for the platform, administration, security controls or frontline support
    • Workspaces, workflow execution and notebook environments included
    • Available on Google Cloud and Microsoft Azure
  • Cloud consumption$undefined/month
    • Google Cloud or Azure charges passed through at cost with no markup
    • Running notebook virtual machines around 0.22 USD per hour, roughly 0.027 USD per hour when paused
    • Storage billed continuously on workspace buckets and intermediate workflow outputs

Which should you pick?

Choose Genedata if

  • You need screener.
  • You work on Web, On-premise, Private cloud.
  • You also want biologics.
Genedata review

Choose Terra if

  • You need no platform licence fee.
  • You want to start without paying.
  • You work on Web, Google Cloud, Microsoft Azure.
  • You also want cloud pass-through billing.
Terra review

Questions people ask

Is Genedata or Terra better?
Neither clearly leads. Genedata starts at On request and Terra at Free, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Genedata or Terra?
Terra has a free tier; the other does not. Paid plans start at On request for Genedata and Free for Terra.
Does Genedata or Terra run on more platforms?
Genedata runs on Web, On-premise, Private cloud. Terra runs on Web, Google Cloud, Microsoft Azure.
Can I use Terra for free?
Yes. Terra has a free tier, so you can try it without paying. Genedata starts at On request.
What is Genedata best used for?
Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Terra is typically brought in for.
What can Genedata do that Terra cannot?
Genedata covers Screener, Biologics, Bioprocess, Expressionist. Terra covers No platform licence fee, Cloud pass-through billing, WDL workflow execution, Notebook environments.

Answered from the vendors’ own pages

Genedata: Who owns Genedata?

Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.

Terra: Is Terra really free?

The platform is. There is no licence fee. Everything you pay is Google Cloud or Azure compute, storage and egress, passed through at cost.

Genedata: Is there a small-team or starter option?

No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.

Terra: What actually drives the bill?

Running virtual machines and stored data. Pausing notebooks drops a virtual machine from about 0.22 to about 0.027 dollars an hour, and deleting intermediate workflow outputs is the other main saving.

Genedata: Do I buy one product or the whole suite?

Each platform is licensed separately. Most customers license two or three and integrate between them.

Terra: Can I use it with protected health information?

Yes. Terra signs HIPAA business associate agreements and GDPR data processing agreements, and the Azure deployment holds FedRAMP Moderate authorisation.

Genedata: Can it be used in a GxP environment?

Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.

Terra: Is it validated for clinical or GxP use?

No. It is a research platform. Regulated clinical or submission workflows need validation and controls you build yourself.

Share

Related pages

More on Genedata

More on Terra

Keep looking

Other head to heads